Abstract
Objective To prioritize circulating metabolites that likely play causal roles in the development of multiple sclerosis (MS).
Methods Two-sample Mendelian randomization analysis was performed to estimate the causal effects of 571 circulating metabolites on the risk of MS. Genetic instruments for circulating metabolites were obtained from three previous genome-wide association studies (GWAS) of the blood metabolome, while genetic associations with MS were from a large GWAS by the International Multiple Sclerosis Genetics Consortium. The primary analysis was performed with the multiplicative random-effect inverse variance-weighted method, while multiple sensitivity analyses were conducted with the weighted median, weighted mode, MR-Egger, and MR-PRESSO.
Results A total of 29 metabolites had suggestive evidence of causal associations with MS. Genetically instrumented levels of serine (OR = 1.56, 95% CI = 1.25 – 1.95), lysine (OR = 1.18, 95% CI = 1.01 – 1.38), acetone (OR = 2.45, 95% CI = 1.02 – 5.90), and acetoacetate (OR = 2.47, 95% CI = 1.14 – 5.34) were associated with a higher MS risk. Total cholesterol and phospholipids in large very-low-density lipoprotein were associated with a lower MS risk (OR = 0.83, 95% CI = 0.69 – 1.00; OR = 0.80, 95% CI = 0.68 – 0.95), but risk-increasing associations (OR = 1.20, 95% CI = 1.04 – 1.40; OR = 1.13, 95% CI = 1.00 – 1.28) were observed for the same two lipids in very large high-density lipoprotein.
Conclusions Our metabolome-wide Mendelian randomization study prioritized a short list of circulating metabolites, such as serine, lysine, acetone, acetoacetate, and lipids, that likely have causal associations with MS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the University of Georgia Research Foundation and by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM143060.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-lead author
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos